Immunovant’s first-generation FcRn inhibitor flunked a pair of phase 3 eye disease trials, appearing to end the last hopes of ...

After the FDA placed two of its next-gen HIV drugs on clinical hold last June, Gilead Sciences has now terminated one of the ...

In the world of clinical trials, missing the primary endpoint of a pivotal trial typically spells real trouble for a drug ...

The number of drugs in development has fallen for the first time since the mid-1990s, according to a Citeline report. | The ...

Another phase 3 trial, Chestnut, evaluated children who switched from Strensiq to efzimfotase alfa. The study showed ...

Have we passed the peak of biotech layoffs? It’s too early to say for certain—but an intriguing story is playing out in the ...

Ambrosia Biosciences is aiming to move the market beyond peptide-based obesity treatments and initiate a trial for its oral ...

Two separate randomized trials of Johnson & Johnson’s miniaturized Impella heart pumps failed to illustrate the devices’ ...

Astellas Pharma has become the latest company to pull back from a potential treatment for Sjögren’s syndrome, an autoimmune ...

After securing a multibillion-dollar biobucks deal with AstraZeneca and raising nearly $100 million last year, peptide drug ...

Boehringer Ingelheim may have been on a spending spree for licensing deals so far this year—but the German pharma has plenty ...

Wave Life Sciences linked its obesity drug candidate to a 1% dip in body weight after six months, leading investors to drive ...